<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254552</url>
  </required_header>
  <id_info>
    <org_study_id>ISO-44-011</org_study_id>
    <nct_id>NCT01254552</nct_id>
  </id_info>
  <brief_title>Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis</brief_title>
  <acronym>ACCREDIT</acronym>
  <official_title>Assessment With Cardiac Computed Tomography Angiography (CCTA) and Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aimed to prospectively investigate the prevalence of myocardial scar on
      Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients
      with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery
      disease on Cardiac Computed Tomography Angiography (CCTA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients underwent a cardiac MRI examination with Dotarem within 60 days after screening
      visit. The myocardial CCTA examination with Xenetix 350 was performed within 1 to 30 days
      (but no sooner than 24 hours) after the MRI examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus</measure>
    <time_frame>From 1 week to 2 months (after the collection of data corresponding to cardiac MRI and CCTA examinations)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis</measure>
    <time_frame>From 1 week to 2 months (after the collection of data corresponding to cardiac MRI and CCTA examinations)</time_frame>
    <description>The degree of coronary artery stenosis on CCTA was assessed according to the following scale:
No stenosis: 0%
Non significant stenosis: 1-50%
Significant stenosis &gt;50% and â‰¤99%
Occlusion: 100%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Dotarem and Xenetix 350</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iobitridol</intervention_name>
    <description>Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.</description>
    <arm_group_label>Dotarem and Xenetix 350</arm_group_label>
    <other_name>Xenetix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoterate meglumine</intervention_name>
    <description>Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)</description>
    <arm_group_label>Dotarem and Xenetix 350</arm_group_label>
    <other_name>gadoteric acid</other_name>
    <other_name>Dotarem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with onset of type 2 diabetes occurred at age 30 years or older

          -  Patient between the ages of 50 and 75 years at enrolment time

          -  Patient with at least two identified cardiac risk factors who will undergo a CMR and a
             CCTA examinations to evaluate his/her coronary and cardiac status

        Exclusion Criteria:

          -  Patient with angina pectoris or chest discomfort

          -  Patient with stress test or invasive coronary angiography within the prior 3 years

          -  Patient with history of myocardial infarction, overt non compensated heart failure, or
             coronary revascularization

          -  Patient with hemodynamic instability.

          -  Patient with a contraindication or intolerance to Beta-Blocker administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>February 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dotarem and Xenetix 350</title>
          <description>All patients were planned to undergo a MRI examination with Dotarem and a myocardial CCTA examination with Xenetix 350 to evaluate his/her coronary and cardiac status.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Delayed-enhanced MRI With Dotarem</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>CCTA With Xenetix 350</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Included Patients</title>
          <description>All patients included in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="348"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.18" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus</title>
        <time_frame>From 1 week to 2 months (after the collection of data corresponding to cardiac MRI and CCTA examinations)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intention To Treat Population</title>
            <description>All patients with a valid MRI and CCTA examinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>rate</param_type>
            <param_value>0.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis</title>
        <description>The degree of coronary artery stenosis on CCTA was assessed according to the following scale:
No stenosis: 0%
Non significant stenosis: 1-50%
Significant stenosis &gt;50% and â‰¤99%
Occlusion: 100%</description>
        <time_frame>From 1 week to 2 months (after the collection of data corresponding to cardiac MRI and CCTA examinations)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Without Occult Myocardial Scar</title>
            <description>Patients without Occult Myocardial Scar on cardiac MRI</description>
          </group>
          <group group_id="O2">
            <title>Patients With at Least One Occult Myocardial Scar</title>
            <description>Patients with at least one Occult Myocardial Scar on cardiac MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis</title>
          <description>The degree of coronary artery stenosis on CCTA was assessed according to the following scale:
No stenosis: 0%
Non significant stenosis: 1-50%
Significant stenosis &gt;50% and â‰¤99%
Occlusion: 100%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No stenosis: 0%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-significant stenosis: 1-50%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Significant stenosis: &gt;50% and â‰¤99%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Occlusion: 100%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signature of the informed consent form until 30 minutes after the end of CCTA examination i.e. from 2 days to 3 months</time_frame>
      <desc>The analysis of adverse events was performed on the safety population that includes all patients receiving at least one injection of contrast agent regardless of the quantity. Post-injection AEs collected between Dotarem and Xenetix 350 injection, during Xenetix 350 injection and after Xenetix 350 injection are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Between Dotarem and Xenetix 350 Injection</title>
          <description>Adverse events that occurred after Dotarem injection (MRI examination) and before Xenetix 350 injection (CCTA examination)</description>
        </group>
        <group group_id="E2">
          <title>During Xenetix 350 Injection</title>
          <description>Adverse events that occurred during injection of Xenetix 350 (CCTA examination)</description>
        </group>
        <group group_id="E3">
          <title>After Xenetix 350 Injection</title>
          <description>Adverse events that occurred after the injection of Xenetix 350 (CCTA examination)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corinne Dubourdieu, Head of Clinical Projects and Medical Writing</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33(0)1 45 91 50 00</phone>
      <email>corinne.dubourdieu@guerbet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

